Neurobiology and Physiology of the Endocannabinoid System

Inbunden, Engelska, 2023

Av Vinood B. Patel, Victor R Preedy, Colin R. Martin, UK) Patel, Vinood B. (Reader, University of Westminster, London, UK) Preedy, Victor R, BSc, PhD, DSc, FRSB, FRSPH, FRCPath, FRSC (Professor, Department of Clinical Biochemistry, King’s College Hospital, London, UK; Emeritus Professor, Faculty of Life Sciences and Medicine, King’s College London, UK Visiting Professor, University of Hull, UK) Martin, Colin R., BSc, MSc, PhD, MBA, YCAP, FHEA (Visiting Professor of Perinatal Wellbeing, Institute for Health and Wellbeing, University of Suffolk, Ipswich, Victor R. Preedy, Vinood B Patel, Colin R Martin

3 229 kr

Beställningsvara. Skickas inom 5-8 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Neurobiology and Physiology of the Endocannabinoid System offers readers a comprehensive reference on the neurobiology of this system and the use of cannabimimetic compounds to induce neurological changes and confer symptom relief. With sections on both natural and synthetic compounds, the book's broad coverage allows readers to learn about their use with multiple conditions, as well as the working biology of the endocannabinoid system, its receptors and its ligands. This volume provides a platform for research on the effects of this system and its modulation in brain function and neurological dysfunction.

Summarizes research on the working neurobiology of the endocannabinoid system
Contains chapter abstracts, key facts, a dictionary and a summary
Covers both natural cannabinoids and synthetic or exogenous cannabimimetics
Includes conditions like headache, anxiety, stress and neuroinflammation
Discusses system modulation in the context of pain, traumatic brain injury and obesity

Produktinformation

Utgivningsdatum2023-09-06
Mått216 x 276 x 39 mm
Vikt1 900 g
FormatInbunden
SpråkEngelska
Antal sidor600
FörlagElsevier Science
ISBN9780323908771

Tillhör följande kategorier

Dr. Patel is a Reader at the University of Westminster. After completing his PhD at King’s College London, he continued his research experience by undertaking his post-doctoral studies in the laboratory of Professor Cunningham in the Department of Biochemistry at the Wake Forest University School of Medicine, (Winston-Salem, NC, USA). This extensive project involved investigating mechanisms of hepatic mitochondrial ribosome dysfunction in alcoholic liver disease (ALD) using biophysical and proteomic techniques. These studies have led to new avenues in determining the pathology of ALD. His teaching areas at both post-graduate and undergraduate levels include clinical biochemistry, investigative pathology and laboratory investigation. Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books. Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.

PrefaceI. Setting the scene and introductory chapters1. Distribution of the endocannabinoid system: linking signalling and developmentMichaela Dvorakova and Anna Kalinovsky2. The endocannabinoid system, immunomodulation, and LPS-induced inflammationElliot Lloyd, Nina Nguyen and Judith Hellman3. Physiology of the endocannabinoid systems: imaging and the use of positron emission tomography (PET)Claudia Poluga, Cassis Varlow, Neil Vasdev, Isabelle Boileau and Laura M. Best4. The endocannabinoid system and agingProf. Vahid Reza Askari5. The endocannabinoid system and post traumatic stress disorder (PTSD): a new narrativeLuke Ney, Kevin M. Crombie and Leah M. MayoII. Neurobiology of the endocannabinoid system6. The protective effect of the endocannabinoid system in neurotoxin induced damage to hippocampal neurons: a focus on light and electron microscopy Rita Yakovlevna Gordon, Valentina Kitchigina and Irina Mikheeva7. Endocannabinoid Signaling and excitatory and inhibitory synapsesJian Liang and Corette J. Wierenga8. The endocannabinoids and potassium channels: an updated narrative Yu-Fung Lin9. Social interactions and neural activity: linking cellular studies and endocannabinoid signalling Cheryl McCormick10. Exercise and Parkinson's disease: linking in the cannabinoid type 1 (CB1) and type 2 (CB2), and mu-opioid receptorsMarucia Chacur Sr., Caroline Cristiano Real Gregório and Karina Henrique Binda11. Endocannabinoids and inhalant misuse: neuropsychological aspectsJohn Woodward12. Fatty acid amide hydrolase (FAAH) in substance use disorders: FAAH regulation and inhibition in cannabis, alcohol, nicotine, stimulant, and opioid use disordersGarth E. Terry and Greta Niemela13. Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: interlinking the endocannabinoid systemStevan Pecic and Ram Kandasamy14. WWL70: linking the hydrolyses 2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways: therapeutic potential and neurological diseaseMikiei Tanaka and Yumin Zhang15. Endocannabinoid catabolic enzyme inhibitors and pain alleviation Sidney Stevens Negus and Clare Diester16. The endocannabinoid system in health and disease: features in epilepsyChristopher Martínez-Aguirre, Maria de los Angeles Nuñez-Lumbreras and Luisa Lilia Rocha17. The endocannabinoid system and autoimmune demyelination: a focus on multiple sclerosisAna Bernal-Chico, Andres Baraibar, Alvaro Moreno-Garcia, Teresa Colomer, Ester Sanchez, Carmen Utrilla, Carlos Matute and Susana Mato18. Endocannabinoid signaling and the lateral habenulaJiang-Hong Ye19. On the interplay among endocannabinoid, noradrenergic and glucocorticoid systems: evidence from aversive memory studiesMoisés Dos Santos Corrêa, Raquel Fornari, Cristina A. Stern, Leandro José Bertoglio and Lucas GazariniIII. Receptor biology and responses 20. Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation Ester Aso and Francisco Ciruela21. Hippocampal CB1, CB2 receptors, the endocannabinoid system and fear memory Ana Maria Raymundi and Cristina A. Stern22. Beta-caryophyllene, the CB2 cannabinoid receptor-specific agonists and wound healing Prof. S. Koyama and Thomas Heinbockel23. The nigrostriatal dopaminergic pathway: impact of WIN 55212-2 as a potent cannaboinoid receptor agonist Enzo Perez-Valenzuela and Jose Antonio Fuentealba Evans24. Peripheral cannabinoid receptor 1 antagonists and impact on adipocytes Morvarid Kabir25. Endocannabinoid system receptors in plasma membranes : extraction, lipid rafts and the cortex Changiz Taghibiglou and Hajar Miranzadeh Mahabadi26. Applications to wound healing: cannabinoid receptor 1 antagonism and collagen depositionInês Correia-Sa27. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a component of the endocannabinoid system, in anxiety, depression, and cocaine addictionCarmen S. Maldonado-Vlaar and Wickensonn Norze28. Allosteric modulators of the endocannabinoid system: Org27569 and cannabinoid receptor 1 (CB1)Dai Lu29. Naturally occurring DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2 receptors: Linking in the endocannabinoid systemIrene Reyes-Resina, Rafael Rivas-Santisteban, Iu Raïch, Claudia Llinás del Torrent, Jaume Lillo, Rafael Franco and Gemma NavarroIV. Profiles and behaviour of selective endocannabinoids30. New cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid systemManuel Faundez-Parraguez31. Fatty acid amide hydrolase, the endocannabinoid anandamide and neurological disease Filomena Fezza32. The endocannabinoid-system in the immuno-biology of dendritic cells Dipyaman Ganguly33. Palmitoylethanolamide and other anandamide congeners in neuroinflammation-based disorders: linking in the endocannabinoid system Enza Palazzo34. Endocannabinoid modulation of synaptic function and behavior in the dorsomedial hypothalamusKaren M. Crosby35. Key role of anandamide and the endocannabinoid system in the modulation of cardio-renal homeostasisProf. Virna M. Martín Gimenez and Walter Manucha36. The endocannabinoid system: Signaling and social motivationRoberta Monterazzo Cysneiros and Fernanda RibeiroV. Exogenous, synthetic other compounds linking in the endocannabinoid system37. Safety and toxicology of the dietary cannabinoid beta-caryophylleneProf. George Oliveira Sr., Bruna Silva, Ana Santos C. L. da Silva and Luciano Silva Lopes38. Synthetic cannabimimetics: an overview Prof. M. KassiouVI. Compartive studies in non neurological systems 39. Non Neurological Aspects of the　 Endocannabinoid System: Non Alcoholic Fatty Liver DiseaseDr. R. Ghazali40. Components of the Endocannabinoid system: Hepatic expression levels of the cannabinoid receptors and microRNAsSema Bolkent and Zeynep Mine Coskun41. Tumour growth and the endocannabinoid system: investigating CB2 agonistsJosee Guindon, Isabel Castro-Piedras, Melissa McHann and Robert Barnes42. Linking Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of therapeutic outcomesSusanna Molinari, Eleonora Maretti, Renata Battini and Eliana LeoVII. Resources43. Endocannabinoids and Resources Rajkumar Rajendram